Bortezomib Consolidation Is More Effective Than Observation for Newly Diagnosed Multiple Myeloma

Bortezomib-based regimens used in transplantation-ineligible patients with multiple myeloma have shown to produce good outcomes in U.S. community practice, according to a recent study published online this week in the Journal of Clinical Oncology.
In the U.S. community-based, three-arm phase IIIB, UPFRONT trial, researchers randomly assigned 502 patients to receive 24 weeks of induction therapy with bortezomib-dexamethasone, bortezomib-thalidomide-
Bortezomib-based regimens used in transplantation-ineligible patients with multiple myeloma have shown to produce good outcomes in U.S. community practice, according to a recent study published online this week in the Journal of Clinical Oncology.
In the U.S. community-based, three-arm phase IIIB, UPFRONT trial, researchers randomly assigned 502 patients to receive 24 weeks of induction therapy with bortezomib-dexamethasone, bortezomib-thalidomide-

about the author
Lizzy Smith
Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.
More on Treatment Advances
Trending Articles





Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.